Evaluation of the cost-effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (peritonectomy) at the st george hospital peritoneal surface malignancy program

Annals of Surgery

Volumn 251, Issue 2, 2010, Pages 323-329

  Chua, Terence C ^a   Martin, Samantha ^b   Saxena, Akshat ^a   Liauw, Winston ^c   Yan, Tristan D ^a   Zhao, Jing ^a   Lok, Irene ^b   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

^c NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; MITOMYCIN C;

ADULT; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOREDUCTIVE SURGERY; DIGESTIVE SYSTEM CANCER; FEMALE; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OVARY CANCER; PERITONEUM CANCER; PERITONEUM MESOTHELIOMA; PERITONEUM PSEUDOMYXOMA; PRIORITY JOURNAL; TREATMENT OUTCOME; CARCINOMA; COST BENEFIT ANALYSIS; ECONOMICS; HYPERTHERMIC THERAPY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PERITONEUM TUMOR; PROSPECTIVE STUDY; REGIONAL PERFUSION; SURVIVAL RATE;

CARCINOMA; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 77449155968     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181c9b53c     Document Type: Article

References (28)

1. Sugarbaker P. Peritoneal Carcinomatosis: Drugs and Diseases. Boston MA: Kluwer 1996.
2. Koppe MJ, Boerman OC, Oyen WJ, et al. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg. 2006;243:212-222.
3. Sakai K, Kamura T, Hirakawa T, et al. Relationship between pelvic lymph node involvement and other disease sites in patients with ovarian cancer. Gynecol Oncol. 1997;65:164-168.
4. Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 2006;7:925-934.
5. Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545-1550.
6. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358-363.
7. Amikura T, Aoki Y, Kase H, et al. Survival of patients with advanced ovarian cancer treated with intermittent chemotherapy following cytoreductive surgery and adjuvant chemotherapy. Int J Clin Oncol. 2002;7:45-50.
8. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29-42.
9. Di Giorgio A, Naticchioni E, Biacchi D, et al. Cytoreductive surgery (peri-tonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008;113:315-325.
10. Yan TD, Black D, Savady R, et al. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemo-therapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006;24:4011-4019.
11. Yan TD, Black D, Savady R, et al. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2007;14:484-492. (Pubitemid 46175292)
12. Yan TD, Welch L, Black D, et al. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007; 18:827-834. (Pubitemid 47054078)
13. Chua TC, Yan TD, Saxena A, et al. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg. 2009;249:900-907.
14. McQuellon RP, Danhauer SC, Russell GB, et al. Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperther-mic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2007; 14:1105-1113.
15. McQuellon RP, Russell GB, Shen P, et al. Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin. Ann Surg Oncol. 2008;15:125-133.
16. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996; 82:359-374.
17. NSW Health. Program and Product Data Collection Standards. In: Branch GF I, ed. Sydney, Australia: NSW Health; 2007/08
18. AIHW. Health System Expenditures on Cancer and Other Neoplasms in Australia, 2000-2001. Vol.22. Canberra, Australia: Australian Institute of Health and Welfare; 2005.
19. Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63:364-367.
20. Witkamp AJ, De Bree E, Van Goethem AR, et al. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev. 2001;27:365-374.
21. Neumann PJ. Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers. Oxford, United Kingdom: Oxford University Press; 2005
22. NHMRC. How to compare the costs and benefits: evaluation of the economic evidence. Canberra, Australia: Commonwealth of Australia 2001.
23. Lo CH, Bohmer RD, Blomfield PI. An evidence-based approach: sugarbaker protocol and pseudomyxoma peritonei of appendiceal origin. ANZ J Surg. 2008;78:327-328.
24. Yan TD, Links M, Fransi S, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malig-nancy-a journey to becoming a nationally funded peritonectomy center. Ann Surg Oncol. 2007;14:2270-2280.
25. Bonastre J, Chevalier J, Elias D, et al. Cost-effectiveness of intraperitoneal chemohyperthermia in the treatment of peritoneal carcinomatosis from colo-rectal cancer. Value Health. 2008;11:347-353.
26. Bristow RE, Santillan A, Diaz-Montes TP, et al. Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis. Cancer. 2007;109:1513-1522.
27. Havrilesky LJ, Secord AA, Darcy KM, et al. Cost effectiveness of intraperi-otneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2008;26:4144-4150.
28. Greving JP, Vernooik F, van der Graaf Y, et al. Is centralization of ovarian cancer care warranted? A cost-effectiveness analysis. Gynecol Oncol. 2009; 113:68-74